Original articlesSubmacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: ii. quality of life outcomes submacular surgery trials pilot study report number 2☆
Section snippets
Methods
The methods of the Submacular Surgery Trials Pilot Study were similar to those described in detail in the Submacular Surgery Trials Manual of Procedures.27 The design and methods of each Submacular Surgery Trials pilot trial, including the health-related quality-of-life interviews, were reviewed and approved by the local institutional review board of each participating center before patient enrollment was initiated at that center. Each patient gave written consent, using a consent form approved
Results
Of the 70 patients who enrolled in this pilot trial, 55 (79%) enrolled at one of the 11 clinical centers that participated in quality-of-life data collection and thus were eligible for an interview at baseline. Of those eligible, 54 (98%) were interviewed before enrollment; the remaining patient was interviewed before having the assigned treatment (surgery) but after enrollment and randomization. Except for two patients, one in each treatment arm, who died during the second year of follow-up,
Discussion
The treatment arm comparisons based on the structured SF-36 interviews are consistent with the ophthalmic findings reported elsewhere for this pilot trial.26 No appreciable differences in either health-related quality of life or ophthalmic outcomes were found between treatment arms. Physical Component Summary scores and Mental Component Summary scores for the pilot trial patients were similar to those of a sample of the general US population of women and men of similar age.28
Given the ages of
Acknowledgements
Submacular Surgery Trials Executive Committee responsible for editorial review of this report: Neil M. Bressler, MD, Chair; Eric B. Bass, MD, MPH; Susan B. Bressler, MD; Mary Frances Cotch, PhD; Hans E. Grossniklaus, MD; Julia A. Haller, MD; Barbara S. Hawkins, PhD; Jennifer L. Holton; Carol M. Mangione, MD, MSPH; Peggy R. Orr, MPH, COMT; Steven D. Schwartz, MD; Jack O. Sipperley, MD; Paul Sternberg, Jr, MD; Matthew A. Thomas, MD; George A. Williams, MD.
References (28)
- et al.
Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study
Ophthalmology
(1996) - et al.
New visual acuity charts for clinical research
Am J Ophthalmol
(1982) - et al.
The Framingham Eye Study Monograph. An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975
Surv Ophthalmol
(1980) - et al.
Common causes of blindness and visual handicap in the west of Scotland
Br J Ophthalmol
(1983) - et al.
Blindness and partial sight in an elderly population
Br J Ophthalmol
(1986) - et al.
Prevalence of ocular disease and blindness in a rural area in the eastern region of Iceland during 1980 through 1984
Acta Ophthalmologica
(1987) - et al.
Racial differences in the cause-specific prevalence of blindness in East Baltimore
N Engl J Med
(1991) - et al.
The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity
Invest Ophthalmol Vis Sci
(1995) - et al.
Current trends in newly registered blindness in Denmark
Acta Ophthalmologica Scand
(1996) Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials
Arch Ophthalmol
(1986)
Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials
Arch Ophthalmol
Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial
Arch Ophthalmol
Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials
Arch Ophthalmol
Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial
Arch Ophthalmol
Cited by (41)
Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration
2018, American Journal of Ophthalmology Case ReportsAssessment of patient-reported outcomes in retinal diseases: a systematic review
2017, Survey of OphthalmologyProgressive Visual Loss in Subfoveal Exudation in Age-related Macular Degeneration: A Meta-analysis Using Lineweaver-Burke Plots
2007, American Journal of OphthalmologyCitation Excerpt :Data for modeling of the natural progression of disease were obtained from the control, untreated eyes in the following studies: the Macular Photocoagulation Study,4 Treatment of Age-related Macular Degeneration With TAP Study,29 Pegaptanib for Neovascular Age-related Macular Degeneration Study,33 Submacular Surgery Trials,40 anecortave acetate trial30–32 and the 360 degree Macular Translocation Study (MT360; macular translocation with 360-degree retinectomy).41,42
Quality of life in patients with age-related macular degeneration: Impact of the condition and benefits of treatment
2005, Survey of OphthalmologyCitation Excerpt :Nevertheless, preserving reading ability may help to preserve QOL for many patients. In a supplementary analysis of the results of a 2-year comparative trial of submacular surgery and laser photocoagulation in 70 patients with recurrent CNV secondary to AMD, the Submacular Surgery Trials Group evaluated general health-related QOL outcomes, using Short Form-36 data obtained at baseline from 54 of the patients.1,4 There were no significant differences in clinical outcomes between the treatment groups in this study, so it may not be surprising that the health-related QOL outcomes from this study were similar in patients treated with laser photocoagulation or submacular surgery.
Quality of life after macular translocation with 360° peripheral retinectomy for age-related macular degeneration
2005, OphthalmologyCitation Excerpt :The SF-36 PCS and MCS of patients who received either focal confluent laser or submacular surgery for subfoveal choroidal neovascularization were compared at baseline and 2 years after treatment. The QOL scores at baseline and throughout the follow-up period were similar in both treatment groups, probably due to similar ophthalmic outcomes in both treatment arms.18 The lack of association between QOL and visual outcomes was further compounded by the limited ability of the SF-36 to detect changes in visual function.8
- ☆
Funding for the Submacular Surgery Trials Pilot Study was provided through awards R21 EY10823 and U10 EY 11547 from the National Eye Institute of the National Institutes of Health, Bethesda, Maryland, and by donations to the Submacular Surgery Trials Research Fund from Alcon, Ft. Worth, Texas; Altsheller-Durrell Foundation, Louisville, Kentucky; Baylor College, Department of Ophthalmology, Houston, Texas; Cleveland Clinic Foundation, Cleveland, Ohio; Duke Eye Center, Durham, North Carolina; Grieshaber and Company, Schaffhausen, Switzerland; Humana of Lexington, Lexington, Kentucky; Ohio State University, Department of Ophthalmology, Columbus, Ohio; Presbyterian-St. Luke’s Hospital, Chicago, Illinois; Research to Prevent Blindness, Inc., New York, New York; Retina Associates of Cleveland, Cleveland, Ohio; Retina Associates of Florida, Tampa, Florida; Retina-Vitreous Consultants, Pittsburgh, Pennsylvania; Richardson Family Trust, Pittsburgh, Pennsylvania; Scheie Age-Related Macular Degeneration Research Fund, Philadelphia, Pennsylvania; Synergetics, Inc., St. Charles, Missouri; University of Miami, Department of Ophthalmology, Miami, Florida; William Beaumont Hospital, Royal Oak, Michigan; and the Wilmer Ophthalmological Institute’s Clinical Trials and Biometry Research Fund, Macular Research Fund, and Vitreoretinal Gift Fund, Baltimore, Maryland.
- ∗
A listing of all Submacular Surgery Trials Pilot Study investigators and personnel who contributed to this pilot trial and preparation of this report appears at the end of Submacular Surgery Trials Pilot Study Report Number 1. The members of the Submacular Surgery Trials Patient Centered Outcomes Subcommittee and Writing Committee for this report are Eric B. Bass, MD, MPH (Patient Centered Outcomes Subcommittee Co-chair); Neil M. Bressler, MD (Submacular Surgery Trials Chair); Susan B. Bressler, MD (Submacular Surgery Trials Executive Committee Representative); Li Ming Dong, PhD (Statistician); Barbara S. Hawkins, PhD (Writing Team Chair); Carol M. Mangione, MD, MSPH (Patient Centered Outcomes Subcommittee Chair); Marta J. Marsh, MS (Statistician); Paivi H. Miskala, MSPH (Writing Team Co-chair); Steven D. Schwartz, MD (Submacular Surgery Trials Executive Committee Representative).